Navigation Links
AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
Date:11/12/2008

QUEBEC CITY, Nov. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its third quarter 2008 financial and operating results on Thursday, November 13, 2008 at 7:30 a.m. The Company will host a conference call and webcast to discuss these results later that same day at 10:00 a.m., Eastern Time.

Participants may access the conference call by dialing the following numbers: 416-646-3095, 514-807-8791 or 800-814-4859. They may also access the live webcast via the Company's website at http://www.aezsinc.com in the "Investors" section. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at http://www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015 ... von der Assistance Publique - Hôpitaux de ... ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie für ... wurden. Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem ... oder Sorafenib behandelt wurden. Die Ergebnisse werden ...
(Date:3/5/2015)... 5, 2015  DuPont (NYSE: DD ) ... Industrials Conference held today in New York ... Trerotola discussed strategy, progress and plans to accelerate ...  Strengthening and growing the company,s leading position in high-value ... strategic priority for DuPont. Discussing the company,s ...
(Date:3/5/2015)... -- Twelve patients today are preparing to participate in a ... Pacific Medical Center (CPMC), a Sutter Health affiliate. ... the largest single-center kidney paired donation chain conducted on ... 44-year history of the CPMC Transplant Center. The two-day ... donor who did not have a specific recipient in ...
(Date:3/5/2015)... --  HX360 today announced that sixteen companies have ... Challenge competition. These companies, selected from a field ... one of four finalists to present their solutions live ... venture capitalists during the Innovation Challenge event. ... 2015 HIMSS Annual Conference & Exhibition, McCormick Place in ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 2Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 3Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 4HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4
... Corporation (Pink Sheets: MNCN), announced today that its Board ... as the company,s Chief Financial Officer, effective March 4, ... "Pat brings a strong background in finance to Mach ... expertise will be great assets to Mach One as ...
... Inc. (OTC Bulletin Board: VSPC) announced today that the ... 7, 499,169 to VIASPACE on March 3, 2009. ... (humidity) in gas streams for fuel cells and exhaust ... smokestacks. Inventors are Nathan Hurvitz and VIASPACE CEO ...
... 10 CEL-SCI Corporation (NYSE Alternext US: CVM) ... new manufacturing process that could allow drugs developed using ... potency and thereby potentially also their shelf life. ... may also significantly accelerate the time to market by ...
Cached Biology Technology:Mach One Announces Appointment of Chief Financial Officer 2VIASPACE Granted US Patent 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 4
(Date:3/5/2015)... , March 5, 2015 In Brazil ... of companies already using these solutions and 42 percent planning ... the latter, approximately 25 percent of the companies will be ... While the majority of companies in the region are currently ... the hybrid model will command significant attention in the coming ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of the "Global Biometrics Market ... offering. The market for biometric authentication ... of around 14% till 2020 The ... be increasing security needs, government projects and constant ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... have received grants from the latest round of National ... and Reinvestment Act (ARRA) of 2009. To date, Forsyth ... The recent round of funding includes three highly competitive ... Challenge Grant competition ― only about 500 were funded. ...
... Boston Whaler may sound like the beginning of another James ... net and studies the effects of climate change on insect ... "Our long-term study shows that El Nio, a global climate ... post doctoral fellow who is now a research ecologist at ...
... (October 5, 2009) To help draw attention to National ... has released findings from a new national consumer survey and ... leading cause of death in the U.S. The national ... incorrectly believe that the processes related to heart disease do ...
Cached Biology News:Forsyth receives highly competitive challenge grants 2Panama butterfly migrations linked to El Niño, climate change 2Americans concerned about heart health, but not proactive enough to prevent it 2
Human ABCG2 MAb (Clone 5D3)...
... PP2A1, purified Formulation: 50mM Tris-HCl, ... Brij-35, 0.2mM PMSF, 1mM benzamidine, ... Properites: PP2A1 (Protein Phosphatase 2A1) ... ammonium sulfate precipitation, QSepharose,amino-hexyl agarose, ...
... The Beacon 2000 One-Step FP ... characteristic high and low fluorescence polarization ... users of the Beacon 2000 System. ... the polarization values generated by their ...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
Biology Products: